Navigation Links
New anti-HIV drug target identified by University of Minnesota researchers
Date:12/18/2013

University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.

Complete findings are printed in today's issue of the Journal of Virology.

The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2'-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis. Lethal mutagenesis annihilates HIV by causing it to mutate to the point of extinction.

The compound 3-deazauridine stopped HIV by creating so many mutations in the virus that the virus was no longer able to spread throughout the body by infecting other cells. The other compounds caused early termination of HIV DNA synthesis, again preventing the virus from being able to reproduce. Studies prior to this one determined certain ribonucleosides analogs impact HIV DNA synthesis, a process called reverse transcription. The extent to which they worked was not previously known.

"It's a counterintuitive finding," said University of Minnesota virologist Louis Mansky, Ph.D. "These ribonucleoside analogs were not generally thought to be associated with affecting HIV DNA synthesis a critical step in virus replication. We don't yet know all the details for how these particular compounds stop the virus in its path."

The research, if translatable, will provide a potentially cost-effective and fresh treatment option to counter HIV's rapid evolution and treat HIV resistance to currently approved anti-HIV drugs. Anti-HIV ribonucleoside analogs are less expensive to create in a laboratory than deoxyribonucleoside analogs, which are key in drugs currently used to stop HIV replication and cell spread. Additionally, the similarity of ribonucleoside analogs to deoxyribonucleosides may help speed up the development process to make full use of this target as a wealth of understanding around ribonucleoside analogs already exists.


'/>"/>

Contact: Miranda Taylor
tayl0551@umn.edu
612-626-2767
University of Minnesota Academic Health Center
Source:Eurekalert

Related biology news :

1. Potential drug molecule shows enhanced anti-HIV activity
2. New drug-screening method yields long-sought anti-HIV compounds
3. Anti-HIV drug use during pregnancy does not affect infant size, birth weight
4. Going against the flow: Halting atherosclerosis by targeting micro RNA
5. Targeted synthesis of natural products with light
6. Glucose: Potential new target for combating annual seasonal influenza
7. Stealth maneuver allows nectar bats to target insect prey
8. Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma
9. Targeted treatment can significantly reduce relapse in children with AML leukemia
10. New target identified for preventing bone destruction in diseases such as arthritis and cancer
11. Fruit pest targeted by genomic research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... 7, 2017 Brandwatch , the leading social intelligence ... Prince,s Trust to uncover insights to support its reporting, help ... The UK,s leading youth charity will be using Brandwatch Analytics ... get a better understanding of the topics and issues that are ... ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named a Top ... Hunt Scanlon Media is one of the most respected life science publications in the ... sector. , “It is a great honor for Slone Partners to be part of ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical for ... increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is a ... , To meet this demand, the team at SCIEX has developed a ...
Breaking Biology Technology: